Orgenesis Awarded Maryland Stem Cell Research Fund Grant

GERMANTOWN, MD (Marketwired) - Orgenesis Inc. (OTCQB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient s own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary in Maryland, Orgenesis Maryland, Inc., has been awarded a grant of $420,000 from the Maryland Stem Cell Research Fund (MSCRF). The grant will assist Orgenesis as the company finalizes pre-clinical work in preparation for Phase I and Phase II clinical trials in the United States. The company is located in Germantown, Maryland. We are honored to receive a grant from MSCRF, said Vered Caplan, chairperson and CEO of Orgenesis. The grant will assist us as we continue preparations for Phase I and Phase II clinical trials in the United States. Orgenesis has developed a unique approach of restoring natural insulin production and blood sugar regulation by converting cells from a patient s own liver in
http://bit.ly/1oRU4Vq